OHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone212-682-8452
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees3
OptionableOptionable
OHR Pharmaceutical (NASDAQ:OHRP) Frequently Asked Questions
What is OHR Pharmaceutical's stock symbol?
OHR Pharmaceutical trades on the NASDAQ under the ticker symbol "OHRP."
When did OHR Pharmaceutical's stock split? How did OHR Pharmaceutical's stock split work?
OHR Pharmaceutical's stock reverse split on Monday, February 4th 2019. The 1-20 reverse split was announced on Wednesday, January 23rd 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 1st 2019. An investor that had 100 shares of OHR Pharmaceutical stock prior to the reverse split would have 5 shares after the split.
How were OHR Pharmaceutical's earnings last quarter?
When is OHR Pharmaceutical's next earnings date?
Has OHR Pharmaceutical been receiving favorable news coverage?
Media headlines about OHRP stock have trended positive on Sunday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. OHR Pharmaceutical earned a news sentiment score of 2.4 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the near term.
Who are some of OHR Pharmaceutical's key competitors?
Some companies that are related to OHR Pharmaceutical include ESSA Pharma (EPIX), Nuvo Pharmaceuticals (NRIFF), GTX (GTXI), Provectus Biopharmaceuticals (PVCT), Sernova (SEOVF), BENITEC BIOPHAR/S (BNTC), Fibrocell Science (FCSC), Sunesis Pharmaceuticals (SNSS), Acerus Pharmaceuticals (TRLPF), Eyegate Pharmaceuticals (EYEG), Xenetic Biosciences (XBIO), Onconova Therapeutics (ONTX), Pain Therapeutics (PTIE), Trillium Therapeutics (TRIL) and KITOV PHARMA LT/S (KTOV).
Who are OHR Pharmaceutical's key executives?
OHR Pharmaceutical's management team includes the folowing people:
- Dr. Jason Scott Slakter, CEO, Pres & Director (Age 61)
- Mr. Samuel Backenroth, CFO, VP of Bus. Devel. & Sec. (Age 35)
- Dr. Glenn L. Stoller M.D., Chief Scientific Officer (Age 55)
- Dr. Marlene Modi, Head of Preclinical & Regulatory Affairs
How do I buy shares of OHR Pharmaceutical?
Shares of OHRP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OHR Pharmaceutical's stock price today?
One share of OHRP stock can currently be purchased for approximately $2.11.
How big of a company is OHR Pharmaceutical?
OHR Pharmaceutical has a market capitalization of $5.96 million. OHR Pharmaceutical employs 3 workers across the globe.
What is OHR Pharmaceutical's official website?
How can I contact OHR Pharmaceutical?
OHR Pharmaceutical's mailing address is 800 THIRD AVENUE 11TH FLOOR, NEW YORK NY, 10022. The biotechnology company can be reached via phone at 212-682-8452 or via email at [email protected]
MarketBeat Community Rating for OHR Pharmaceutical (NASDAQ OHRP)
MarketBeat's community ratings are surveys of what our community members think about OHR Pharmaceutical and other stocks. Vote "Outperform" if you believe OHRP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OHRP will underperform the S&P 500 over the long term. You may vote once every thirty days.
